Black Diamond Therapeutics, Inc. business relationships
Companies named in Black Diamond Therapeutics, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name Black Diamond Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 2 / 100 Top 5% in its category
- Agent readiness
- 10 / 100
- AI adoption
- 0 / 100
Named in Black Diamond Therapeutics, Inc.’s annual report 3
“For example, in March 2025, we entered into a global licensing agreement (the Servier Agreement) with Servier Pharmaceuticals LLC (Servier) for our second clinical-stage asset, BDTX-4933, a small molecule designed to address unmet medical needs in RAF/RAS-mutant solid tumors.” SEC filing
“• our partnership with Servier Pharmaceuticals LLC (Servier) and the intended and potential benefits thereof, including the receipt of potential development and commercial milestone payments, along with tiered royalties based on global net sales, if any;” SEC filing
“Based upon real-world evidence gathered in collaboration with Guardant Health, these patients have significant unmet medical needs.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.